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Biology of EBV infection : an overview  
 
Herpesviruses are ancient pathogens whose apparently benign relationship with their host species 
reflects the fine balance struck between host immune controls over virus infection and the virus’ 
ability to evade those controls. Real insight into the immunological battle raging beneath the 
surface comes when that evolutionary compact is disturbed and disease ensues. Nowhere is this 
better illustrated than by Epstein-Barr virus (EBV), the human gamma-1 herpesvirus carried by 
most people as a life-long asymptomatic infection. Figure 1 presents the basic framework of 
EBV infection as currently understood. The main features, in chronologic order, are (i) initial 
replication of orally transmitted virus in permissive cells (probably squamous epithelial cells and 
some locally-infiltrating B lymphocytes) within the oropharynx,, (ii) colonisation of the host 
through growth-transforming latent infection of B cells in oropharyngeal lymphoid tissues, (iii) 
life-long persistence within the re-circulating memory B cell pool as a silent latent infection, and 
(iv) occasional reactivation from latency into virus replicative (“lytic”) cycle, seeding secondary 
foci of virus replication at oropharyngeal sites. 
 
In the process the virus presents an antigenically rich challenge to the immune system. Thus 
virus replication involves the sequential expression of two immediate early, >30 early and >30 
late lytic cycle proteins, while classical B cell growth-transformation is achieved through the 
collective actions of 8 latent proteins, namely the nuclear antigens EBNAs 1, 2, 3A, 3B, 3C and 
–LP plus the latent membrane proteins, LMPs1 and 2. Many of these viral proteins elicit 
antibody and/or cell-mediated immune responses. Among the humoral responses, neutralising 
antibodies, predominantly directed against the virus’ major envelope glycoprotein gp340 (a late 
lytic cycle product), are almost certainly important in longer-term protection of the host from re-
infection by exogenous virus; however, such antibodies are quite slow to develop to high affinity 
during primary infection. Accordingly, cell-mediated responses appear to be more important in 
bringing the primary infection under control and also in containing reactivation of the virus from 
its latent reservoir during long-term virus carriage.  
 
The main effectors of these cellular responses, NK cells, CD4
+
 and CD8
+
 T cells, are 
superimposed onto Figure 1 to show their potential sites of action against infected cells. How 
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important these individual players are, and how they work together to contain EBV as an 
asymptomatic infection, is still poorly understood. Here we review recent lessons on this subject 
that have come either from patients in whom natural infection erupts into disease or from 
experimental infection in two increasingly promising animal models.  
 
    
Infectious mononucleosis  
 
Primary EBV infection in its natural setting, early in life, is almost always asymptomatic. 
However, if delayed until adolescence or later, as often happens in affluent societies, it 
sometimes presents as infectious mononucleosis (IM). This disease is characterized by large 
expansions of activated CD8
+
 T cells and to some extent NK cells appearing in the blood; indeed 
the classical symptoms (fever, pharyngitis, lymphadenopathy) may be caused more by cytokine 
release from those activated cells than from the virus infection per se. However the course of IM 
can vary from mild to severe, and little is known about the risk factors for disease development 
or severity. The most recent insights have come from a 4-year follow-up of 143 EBV-
seronegative college students, involving regular screening at 8 week intervals and immediate 
bleeds on signs of illness [1]. Of the 66/143 students who seroconverted to EBV-positivity over 
that time, 51 developed two or more IM symptoms. Disease severity correlated positively with 
virus load in circulating B cells, with the size of the CD8
+
 T cell response and also with NK cell 
numbers in the blood. Although these findings could not distinguish between virus infection and 
immune pathology as the determinant of symptoms, they did suggest that both CD8
+
 T cells and 
NK cells were responding similarly to the intensity of the viral challenge. The latter point 
remains controversial, however, since earlier work (albeit on a smaller patient cohort) reported 
an inverse correlation between virus load and NK cell numbers in IM blood, and inferred from 
this that severe IM resulted from a deficiency of early NK-mediated control [2]. Further studies 
are needed to resolve this important issue, focusing on the phenotype as well as the number of 
NK cells in IM blood, and (in the rare cases where this is possible) extending the work to include 
an analysis of NK cell, CD8
+
 T cell and EBV-infected B cell populations in IM tonsils, where 
the real action is likely to be found.   
  
As comparators with IM, cases of asymptomatic primary infections are potentially very 
informative but they are difficult to identify without regular screening of large EBV-naïve 
cohorts. The above prospective study of college students [1] did not report on this topic but 
recent work in young children, albeit in Africa, found that viral loads in the blood can be as high 
as in acute IM yet they do not induce obvious lymphocytosis [[3], Jayasooriya and Hislop, 
personal comm]. This is reminiscent of earlier findings, where two of three asymptomatic 
seroconverters identified during screening for a vaccine trial had high EBV loads without large 
CD8
+
 T cell expansions [Silins et al 2001]. Such evidence favours the view of IM as an 
immunopathologic disease, but why CD8 expansion should be more common after acquiring the 
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virus later in life is not understood. Virus load per se cannot be the full story. One suggestion is 
that adults are primed to mount more vigorous CD8
+
 T cell responses because, with age, other 
viral challenges have populated T cell memory with more clonotypes cross-reactive with EBV 
[4]; so far however, prospective studies show no clear evidence of pre-existing CD8
+
 T cell 
responses to other viruses being expanded (or eroded) in IM [5]. Another possibility is that NK 
cell responses assume greater importance, and perhaps are more effective, in combating virus 
infections early in life [6]; this again accords with the idea that effective early control over the 
incoming virus by NK cells can obviate the later need for massive CD8 expansion and its 
associated symptomatology. 
 
Components of the cell-mediated response to EBV   
 
NK and invariant (i-)NKT cell responses  
 
NK cell control of EBV during primary infection may operate at several levels, targeting either 
virus replicative foci in the oropharynx or the latent growth-transforming infections through 
which the virus first colonises the B cell system (see Figure 1). Of the two, virus replication 
would seem the more likely target if only because expression of surface HLA I molecules, the 
ligands for NK inhibitory receptors, falls in lytically-infected cells. In vitro models of lytic 
infection are limited but early studies showed that, at least in a virus-infected Burkitt’s 
lymphoma cell line, the subset of cells entering lytic cycle are indeed sensitised to NK 
recognition [7]. This was coincident not just with surface HLA I down-regulation but also with 
up-regulation of ligands for the NK activating receptors NKG2D and DNAM-1 [7].  If NK cells 
have indeed exerted evolutionary pressure on EBV, one might expect viral counter-measures 
against such recognition, and perhaps the first hint of such NK evasion has recently emerged. 
Thus one of the EBV-coded lytic proteins that impairs HLA class I antigen presentation to CD8
+
 
T cells at the cell surface, BILF1, targets HLA-A and -B molecules but not HLA-C, the ligand 
for certain NK inhibitory receptors of the KIR2DL class [8]. Further insights into the signals 
mediating NK recognition of lytically-infected cells are long overdue. 
As to latent infection, EBV-transformed LCLs are poorly recognised and killed by the cytotoxic 
CD56
dim
, CD16
+
 NK cells that are prevalent in blood, probably reflecting the dominance of 
inhibitory over activating signals mediated by the high HLA I levels seen on transformed B cells 
[Stewart et al, PNAS 2005].  However in secondary lymphoid organs, including the tonsils 
where EBV infection initiates, the NK cell population is dominated by less mature CD56
bright
, 
CD16
-
 cells, some of which are primed for rapid IFN production in response to dendritic cell-
derived IL12 rather than cytotoxicity [9]. The superior ability of tonsillar, as opposed to blood, 
NK cells to limit B cell transformation by EBV in vitro [10] has now been attributed to this high-
IFN-producing CD56bright, CD16- subset [11]. Accordingly, this effect requires the addition of 
NK effectors to the cultures within 2-3 days of B cell infection, that is during a brief initial 
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period in which the B cell transformation process can likewise be delayed (but never ablated) by 
exogenous IFN addition.   
Recent evidence suggests that iNKT cells with the V9/V2 T cell receptor, recognising the -
GalCer-CD1d complex, may also mediate some control over the same in vitro transformation 
process. Thus, although iNKT cell numbers in peripheral blood mononuclear cell (PBMC) 
preparations are typically <0.3%, their depletion using an -GalCer-CD1d tetramer reportedly 
led to a 2-fold increase in the number of activated EBV-infected B cells in PBMC cultures 8 
days post-infection [12]. The mechanism underlying this effect remains to be determined, but 
presumably must operate within 1-2 days of infection before EBV-activated B cells down-
regulate CD1d expression. Importantly, this down-regulation is not evidence of iNKT cell 
evasion by the virus but the programmed response of resting human B cells to any activating 
signal [13]. 
   
CD8
+
 T cell responses  
The cytotoxic CD8
+
 T cell response to primary EBV infection as seen in IM patients has been 
extensively reviewed [14,15] and only certain aspects will be discussed here. Most activated 
CD8
+
 T cells in IM blood are EBV-specific, with lytic-antigen dominant over latent-antigen 
specificities. This dominance becomes less marked as the acute infection subsides and the highly 
expanded lytic-antigen response is more heavily culled. These changes, graphed in Figure 2, are 
consistent with the presumed order of events in primary EBV infection. Early replicative foci 
would be expected to activate responses first from NK cells and then from lytic antigen-specific 
CD8
+
 T cells; thereafter, the virus colonises the B cell pool through latent growth-transforming 
infections that elicit the latent antigen-specific CD8 response.       
The latent cycle proteins are co-expressed in virus-transformed cells yet, as CD8 targets, show a 
marked hierarchy of immunodominance with the strongest responses on many HLA I 
backgrounds recognising epitopes derived from the largest latent cycle proteins, the 
transcriptional regulators EBNAs 3A, 3B and 3C [15]. However there are exceptions; particular 
HLA alleles will induce strong responses against epitopes from one of the usually sub-dominant 
antigens, for example the virus genome maintenance protein EBNA1 [16]. Thus endogenously 
expressed EBNA1 can be a significant CD8 target despite impairment of its HLA I-restricted 
presentation by the protein’s glycine-alanine repeat (GAr) domain; this reflects the fact that the 
impairment is only partial and does not eliminate EBNA1 epitope display [Mackay et al, 2009]. 
Though outside the scope of the present review, readers are referred to papers attributing the GAr 
domain’s action either to its mRNA structure slowing translation [17,18] or to the nascent GAr 
polypeptide itself impairing translation initiation [19,20] .   
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Lytic cycle antigens also display a reproducible hierarchy of immunodominance in donors across 
a range of HLA types, with the numerically strongest responses directed against the two 
immediate early and a subset of early proteins, and much weaker responses against the virion 
structural proteins that are abundantly expressed late in the cycle [21,22]. Interestingly, this 
hierarchy directly matches the falling efficiency with which these successively expressed 
antigens are presented on the lytically-infected cell surface [21], as EBV’s battery of CD8 
evasion proteins take increasing hold (reviewed [23,24]). This correlation between 
immunogenicity and epitope display on infected cells implies either that the CD8
+
 T cell 
response is initially primed by direct contact with lytically-infected B cells (rather than cross-
primed by antigen re-presented in dendritic cells) or, at the least, its subsequent expansion is 
directly driven by such contacts. The arguments favouring direct B cell contact as the main 
driver of EBV-specific CD8
+
 T cell responses are enlarged later (see Figure 3 legend) when 
looking at the possible consequences for antigen choice in individuals with impaired B cell/T cell 
interactions. 
   
CD4
+
 T cell responses  
By contrast, the CD4
+
 T cell response to EBV seems to be spread much more evenly across the 
whole range of available lytic cycle as well as latent antigens, as one might expect from a 
classically cross-primed response [25,26]. There is no marked increase in total CD4
+
 T cell 
counts in acute IM but, with the development of HLA II tetramers, activated EBV epitope-
specific CD4
+
 T cells have been detected at this time [27]. While these individual epitope-
specific responses rarely exceed 1% of all CD4
+
 T cells, collectively they do impact on the 
activation status of the circulating CD4
+
 population in the acute phase. Thereafter tetramer-
staining cell numbers fall rapidly within a few days, suggesting that the response peaks very 
early in the disease course. Again in contrast to the CD8 response, latent antigen-specific CD4 
responses tend to be larger than those directed against lytic antigens both in IM and, after 
contraction, in T cell memory [27]. It is notable that, at least after in vitro expansion, many EBV-
specific CD4
+
 T cell clones have cytotoxic as well as cytokine-secreting abilities [26,27].  This 
implies that the CD4
+
 T cell response may play more than one role in vivo, with some cells 
providing help for the antibody responses to EBV antigens typically seen in IM, and others 
acting as direct cytolytic effectors against virus-infected B cells.  
Intriguingly, the primary CD4 response to EBNA1 displays quite different kinetics, often not 
appearing until months after disease resolution [27]. This matches the well-known serologic 
picture in IM, where the IgG response to EBNA1 is unusually delayed and indeed may never 
appear in rare patients with chronic IM-like symptoms [28-30]. An absence of specific T cell 
help might therefore underlie this previously unexplained feature of the EBNA1 antibody 
response.  As to why the EBNA1-induced T cell response is so delayed, a clue came from studies 
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looking at the recognition of LCLs by CD4
+
 T cell clones specific for EBV antigens naturally 
expressed by these cells. Clones specific for lytic cycle antigens and many clones against latent 
proteins recognised LCLs well. In each case, however, this did not reflect direct recognition of 
antigen-expressing cells; rather, the relevant antigen was being released into supernatant 
medium, then taken up and processed as exogenously-acquired protein by co-resident cells in the 
culture. By contrast, EBNA1 was not detectably released and so its presentation to CD4
+
 T cells 
was entirely dependent on intra-cellular processing of the endogenously expressed protein 
[31,32].   This perhaps explains why only a minority of the known EBNA1 CD4 epitopes are 
displayed on the LCL surface in amounts that are detectable by epitope-specific T cell clones, 
and those that are presented arise through intra-cellular processing pathways such as macro-
autophagy [32,33].  
Figure 2 summarises a kinetic view of events characterising primary infection, from the time IM 
symptoms develop. Note that very little is known about the prior incubation period, although 
some evidence suggests that high virus load in the blood and the accompanying lymphocytosis 
only appear shortly before symptoms [1].  Interestingly, while latent virus load in the blood is 
rapidly brought under control during the disease course , high levels of asymptomatic virus 
shedding can be found in throat washings for several weeks or months [30,34]. This suggests 
either that shedding is occurring from an immunologically protected site in the oropharynx or 
that the particular controls governing shedding are slow to develop and access that site.   
 
EBV infection in primary immunodeficiencies affecting cellular immunity  
While classical IM patients offer one important window into the biology of EBV infection, 
patients with primary immunodeficiencies affecting the NK and/or T cell systems offer another. 
The best known examples, the X-linked lymphoproliferative syndrome (XLP) and its relative 
XIAP, have recently been joined by several other primary immunodeficiencies predisposing to 
EBV-associated disease [reviewed [35]]. These are of considerable interest but require cautious 
interpretation because patient numbers are small and, even where the genetic basis of the 
deficiency is known, its effects are rarely specific to just one arm of the cellular immune system. 
There are currently three genetically-defined conditions with either a selective or preferential  
loss of NK cell function relative to that of T cells  [reviewed [36]]. All three are associated with 
increased susceptibility to various pathogens, including herpesviruses such as herpes simplex 
(HSV1) and varicella (VZV); however EBV is also implicated on occasions. The most NK-
specific deficiency involves patients with a homozygous mis-sense mutation in CD16, the NK 
cell activating receptor for antibody-dependent cell cytotoxicity (ADCC). Interestingly, the 
mutation does not affect NK cell development or ADCC function but does impair spontaneous 
NK-mediated cytolysis [37-39]; among three affected kindreds, there was one case of prolonged 
IM-like illness in infancy and another case of EBV-driven lymphadenopathy. Another condition 
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affecting, among other things, NK but not T cell development arises from homozygous mutation 
of the gene encoding MCM4, a helicase component of the DNA replication complex [40-42]. 
Among the few MCM4-deficient kindreds studied to date, one child developed EBV-positive B-
lymphoproliferative disease (i.e. the in vivo outgrowth of virus-transformed cells, just as occurs 
in T cell-suppressed transplant patients); interestingly this child was the only one of four siblings 
who also failed to mount a T cell-dependent EBNA1 antibody response to EBV infection [40]. 
Finally an overlapping set of clinical presentations, for which an NK cell deficiency with 
susceptibility to herpesvirus infections [43] represents the index case [44], have recently been 
linked to heterozygous mutations of the haemopoietic transcription factor GATA2 [45]. Though 
the haematological picture is varied, most affected individuals show severe depletion of 
circulating NK cells, B cells and monocytes and a partial loss of CD4
+
 T cells. Interestingly, 
perhaps because an absence of B cells would greatly reduce the chance of acquiring EBV,  there 
were only two cases of EBV-associated disease among the 57 patients identified to date and both 
involved unusual EBV-positive malignancies of mesenchymal cells [45]. One was of spindle cell 
origin whereas, significantly, the other was a leiomyosarcoma, a smooth muscle cell tumour  
usually observed only in heavily T cell-compromised patients [46,47] but recently also found in 
a child with a genetically-uncharacterised NK cell deficiency [48].       
Clearly NK cell defects impair host control over the replication of several viruses, including such 
agents as HSV1 and VZV. The same may well be true for EBV but this is less clinically obvious 
because, in contrast to other herpesviruses, uncontrolled EBV replication in its natural setting of 
the oropharynx is either asymptomatic or manifest as non-threatening oral lesions [49]. To what 
extent NK cells have a restraining role over growth-transforming latent EBV infections is less 
clear from the above evidence. The appearance of rare EBV-positive tumours derived from 
atypical cell lineages may well reflect the fact that latent EBV infection is potentially oncogenic 
in many cellular contexts, but that the virus only gains opportunistic access to these other cell 
lineages when virus replication is poorly controlled.   
Three other recently-identified immune deficiencies associated with symptomatic EBV infection 
share a broadly similar immunologic phenotype with normal NK cell numbers, low iNKT cell 
numbers (where examined), and marked T cell lymphopenia, especially affecting naive CD4
+
 T 
cells. These involve homozygous mutations in the genes encoding (i) interleukin2-inducible T 
cell kinase (ITK), a non-receptor tyrosine kinase involved in TCR signalling but also important 
for iNKT cell development [50-52], (ii) coronin1A, an actin regulator involved in TCR 
signalling and T cell homeostasis [53], and (iii) serine-threonine kinase 4 (STK4), with roles in T 
cell homing and function [54,55]. Though many such individuals have a history of recurrent viral 
infections, most have been investigated specifically because of a clear predisposition to EBV-
driven B-lymphoproliferative disease and/or EBV-positive Hodgkin Lymphoma. There was no 
detailed analysis of EBV-specific T cell responses in the above patient cohorts, but the findings 
chime with a wealth of existing evidence from transplant patients receiving T cell-suppressive 
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drugs [reviewed [56]] that T cells exercise the main control over growth-transforming B cell 
infections in vivo.   
However, as more primary immunodeficiencies are genetically mapped and their cohorts 
investigated, three other conditions have been recognised with impaired EBV control despite the 
induction of a sizeable CD8
+
 T cell response. The first is caused by a dominant-activating 
mutation in the catalytic subunit of the phosphatidylinositol-3-OH kinase (PI3K) pathway, 
leading to lymphocyte hyper-activation [57,58]. This typically presents in childhood as 
susceptibility to respiratory infections but, in one report, all 9 affected patients had high EBV 
genome loads in the blood and 2 had developed EBV-positive lymphoma. Patients had large 
numbers of EBV-specific CD8
+
T cells; however, like the CD8
+
 T cell population as a whole, 
these were skewed toward a terminally differentiated, potentially functionally impaired, 
phenotype [58].  
A second such condition involves homologous inactivating mutations in the gene encoding 
CD27, a TNF receptor family member expressed by memory B cells and by all T cells except for 
a late terminally differentiated subset. Perhaps surprisingly, CD27 loss did not affect memory B 
cell development or NK, i-NKT, CD4
+
 and CD8
+
 T cell numbers. However, 8 of 10 affected 
members in three kindreds presented either with severe primary EBV infections, often leading to 
hypogammaglobuinaemia, or with EBV-positive B-lymphoproliferative disease [59,60].  
Surviving patients in both studies had EBV-specific CD8
+
 memory T cell populations that were 
of normal size but markedly skewed towards an IFN-producing (effector-memory) phenotype, 
possibly reflecting on-going antigen challenge in vivo. One interesting possibility is that these 
patients are particularly susceptible to EBV because virus-transformation strongly upregulates 
the CD27 ligand, CD70, on the B cell surface [61], and optimal recognition by EBV-specific 
CD8+ T cells may require the CD27-CD70 interaction as a co-stimulus. 
A final example involves inactivating mutation of the X-linked gene encoding the magnesium 
transporter, MAGT1 [62]. Affected males have normal NK and i-NKT cell numbers but low 
CD4
+
 T cell counts, especially in the naive compartment, and a TCR signalling defect [63]. 
Though susceptible to other infections, all 7 reported patients came to attention through 
persistent IM-like symptoms and high EBV loads, progressing in 4 cases to EBV-positive B-
lymphoproliferative disease or frank lymphoma. These patients had normal numbers of EBV-
specific CD8
+
 memory T cells and NK cells; however, after in vitro expansion, both these 
effectors showed poor recognition of relevant target cell lines. Mg
++
-supplementation of the 
medium corrected the functional deficit by restoring expression of NKG2D both on the NK cells, 
where it serves as an activating receptor, and on the EBV-specific CD8
+
 T cells, where 
interactions with NKG2D ligands on the LCL surface optimised specific recognition. 
Remarkably, treating the MAGT1-deficient patients with Mg
++
 supplements led to falling EBV 
loads in the blood, demonstrating the biological relevance of NK and/or T cell responses in 
setting the viral set-point in vivo [64]. 
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The special case of XLP and its relative XIAP   
The most extreme example of genetic susceptibility to EBV involves young boys in whom 
primary infection leads to X-linked lymphoproliferative disease (XLP), a highly exaggerated 
form of IM, with high viral loads in infected B cells accompanied by massive CD8
+
 T cell and 
NK cell responses [65]. The resultant cytokine storm triggers haemophagocytic  
lymphohistiocytosis (HLH),  leading in most cases to fatal bone marrow failure. Other boys with 
the same trait present with hypogamma-globulinaemia or B cell lymphoma, conditions that are 
not linked to (and may precede) EBV infection [66-68]. The XLP gene SH2D1A encodes a small 
adapter protein, SAP, that is expressed in T, NK and i-NKT cells and is involved in the 
signalling of cell-cell interactions mediated by members of the SLAM family of surface 
receptors [69] Interestingly, XLP patients have normal numbers of NK and T cells but lack i-
NKT cells, fuelling speculation that i-NKT cells may play a role in controlling EBV. However, 
as discussed further below, SAP-negative T and NK cells also have specific functional defects 
that likely contribute to the disease.  
Subsequently, a second X-linked condition with similarities to XLP was discovered and mapped 
to the nearby BIRC4 gene [70]. Its product, the X-linked inhibitor of apoptosis (XIAP) protein, is 
ubiquitously expressed and has both an anti-apoptotic function and multiple signalling pathway 
connections.  Affected boys typically present with HLH symptoms that are often, but not always, 
linked to primary EBV infection; they may also present with hypogamma-globulinaemia but, in 
contrast to XLP, never with lymphoma. Just how close the relationship is between the two 
conditions remains a subject of debate [71,72]. XIAP patients often have low numbers of i-NKT 
cells but normal NK and T cell numbers; however their T cells show an increased sensitivity to 
apoptotic stimuli ex vivo [70,73]. How this immune phenotype relates to the XIAP disease 
phenotype is still poorly understood.  
By contrast, work on SAP has illuminated many aspects of XLP pathogenesis. SAP binds to the 
cytoplasmic tails of SLAM family proteins expressed by NK, T and i-NKT cells and mediates 
signal transmission following the interaction of these proteins with their partners on other cell 
types. Interactions with B cells appear particularly dependent on two SLAM family members; 
one of these, NTBA, forms homotypic interactions with NTBA on the B cell surface whereas the 
other, CD244, binds to a B cell-specific protein, CD48, whose expression is dramatically up-
regulated by EBV infection (see Figure 3). SAP deficiency is therefore especially damaging both 
to physiologic T cell-B cell communication, hence predisposing to hypogamma-globlinaemia 
[69], and to the control of a B-lymphotropic virus: thus NK cells cannot kill HLA class 1-
negative B cell targets [74] and EBV-specific CD8
+
 T cells, though they are induced in XLP 
patients, cannot recognise EBV-infected B cell targets [75]. The same deficient target 
recognition also protects XLP T cells from restimulation-induced cell death, the homeostatic 
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control that normally regulates effector cell numbers [76], hence explaining the extreme 
expansions and associated symptomatology one sees in the fatal IM-like disease.  
The importance of SAP for CD8
+
 T cell control of EBV is most clearly shown by XLP-carrier 
mothers, in whom random X-chromosome inactivation produces both SAP-positive and SAP-
negative populations in the T cell repertoire.  EBV-specific CD8
+
 T cells in these carriers were 
exclusively SAP positive, while CD8
+
 T cells against other viruses were found in both 
populations [77]. Furthermore, careful re-analysis of XLP patients themselves has detected cases 
where small numbers of CD8
+
 T cells have regained SAP function by somatic reversion of the 
SH2D1A gene mutation. Such SAP-positive cells were only detectable in XLP patients who had 
survived EBV infection and indeed those cells appeared to be enriched for EBV-reactivities, 
suggesting that long-term virus carriage had driven the expansion of these rare revertants to 
detectable levels [78]. 
Despite the presence of small reverted populations in most EBV-positive XLP patients studied to 
date, all such patients also have SAP-negative CD8
+
 T cell memory to EBV. Hence they have 
clearly mounted CD8
+
 T cell responses to primary EBV infection even though the SAP-negative 
effectors thus produced recognise EBV-infected B cells very poorly if at all [75,77]. The 
implications for the priming of these responses are illustrated in Figure 3. In XLP patients the 
initial priming and early expansion of the CD8 response might be driven less by direct CD8
+
 T/B 
cell contact, that is by the pathway envisioned for responses in immunocompetent individuals, 
and more by the cross-presenting DC pathway. As a result, the usual hierarchy of CD8 
immunodominance among lytic cycle proteins (immediate early>early>late, reflecting antigen 
display on lytically-infected B cells) should be overturned. In particular, late structural proteins 
of the virus, released in abundance from lytically-infected cells and available to cross-presenting 
DCs, should compete more effectively for immunodominance. Antigen choice would therefore 
become much broader, indeed closer to that shown by the conventionally cross-primed CD4 
response. Screening the hierarchy of EBV antigen specificities within the SAP-negative CD8
+
 T 
cell pool of XLP patients will allow this prediction to be tested.  
 
Lessons from animal models     
Lessons learned from EBV infections in the natural host can take us so far. However many 
outstanding issues, the very early events following infection of the naïve host, the establishment 
of latency in memory B cells, the relative contributions of innate and adaptive responses to 
immune surveillance, can only be resolved with the help of animal models. The restriction of 
gamma1-herpesvirus infections to primate hosts is a major challenge in that regard, but two 
models show particular promise. 
Old World primates carry gamma1-herpesviruses that are genetically very close to EBV, persist 
in the B cell system and elicit both CD4
+
 and CD8
+
 antigen-specific T cell memory [79,80].  
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Furthermore the establishment of a specific pathogen-free colony of rhesus macaques has 
allowed such animals to be orally infected with their natural EBV-like agent, rhesus 
lymphocryptovirus (rhLCV) [81]. As recently reviewed [82], now that the rhLCV genome can be 
manipulated genetically as a Bacterial Artificial Chromosome, the system has the ability to 
identify what role individual virus genes play in the acute and persistent phase of infection. 
Indeed, a serendipitous deletion in the gene encoding rh-BARF1, a secreted lytic cycle protein 
that blocks colony stimulating factor (CSF1) signalling, has already produced interesting results. 
Rh-BARF1 evasion of the host’s innate CSF1 response increases virus replication in the 
oropharynx, and this leads on to higher loads in latent virus in the life-long B cell reservoir [83].     
A second complementary approach uses immunodeficient BALB/c Rag 2
-/-
 c-/- or NOD-scid c-/-  
mice reconstituted with the main human haemopoietic cell lineages from inocula of CD34
+
 
human stem cells from cord blood or foetal liver [reviewed [84]]. Initial studies showed that 
EBV infection of such animals by intraperitoneal injection induced virus-specific CD8
+
 T cell 
responses and that T cell depletion predisposes to virus-driven B-lymphoproliferative disease 
[85-87] . Interestingly, although the virus had to be delivered directly into the B cell system of 
these animals (by-passing the stage of virus replication in the oropharyynx), there was a 
detectable CD8
+
T cell responses to lytic cycle epitopes,  confirming that incoming virus can 
replicate in B cells of the naïve host. Analysing human T cell responses to any virus in such 
animals is complicated by the need to supply a human HLA-expressing thymic epithelium for 
selection of the T cell repertoire, either via HLA transgenesis or using a human thymic tissue-
containing organoid [86,88,89]. However, animals with successful reconstitution of the dendritic 
and NK cell compartments [90-92] allow one to study the very early immune response to virus 
infection, before T cells come into play. Very recent work in such animals has thrown important 
light on the early events of EBV infection [93], detecting marked expansion of NK cells with an 
early-differentiation CD94
+
NKG2A
+
KIR
-
 phenotype. Note that this phenotype is either identical 
to or the next differentiation step after [94] the tonsillar NK cell compartment that showed 
superior inhibition of EBV driven B cell transformation in vitro [10,11].  Antibody-mediated 
depletion of these cells, but not of more differentiated NK cells, led to increased EBV genome 
load in blood and spleen (with especially high DNA-aemia in plasma) and increased expression 
of lytic EBV antigens in infected organs. This effect of NK cell depletion on viral load was only 
observed using wild-type virus, not with a replication-deficient EBV mutant, thereby clearly 
implicating a role for NK cells in controlling early virus replication. Furthermore NK cell 
depletion and the consequent increase in virus load led to a greatly expanded CD8
+
 T cell 
response, associated with elevated cytokine levels and lymphadenopathy; again the effect was 
only observed with replication-competent wild-type virus. These findings provide the first 
experimental evidence, albeit in an animal model, that NK cells and T cells play important 
complementary roles in combating primary EBV infection. As illustrated in Figure 4, they 
suggest that NK cells, particularly the early-differentiated subset that predominates in early 
childhood, act initially to limit lytic EBV replication and thereby avoid the massive expansion of 
virus-specific CD8
+
 T cells that culminates in IM-like immunopathology. 
12 
 
Conclusions and future challenges 
EBV is a very significant human pathogen yet, in most individuals, is carried as a completely 
asymptomatic infection contained by host immune controls.  Given the global impact of EBV-
associated malignant and non-malignant conditions, understanding the full spectrum of those 
immune controls and how their disturbance can lead to disease is a hugely important goal. Here 
we have described three current lines of enquiry that will remain important in pursuing that goal: 
(i) prospective studies on IM and, where possible, on the exaggerated form of this disease seen in 
XLP patients, (ii) monitoring EBV infections in the ever-increasing range of genetically-defined 
primary immune deficiency states, and (iii) experimental EBV infections in the rhesus macaque 
and humanised mouse models. With these studies as a basis, there are many further questions to 
address. How might EBV infection, particularly a history of IM, predispose both to an 
autoimmune disease, multiple sclerosis [95] and to Hodgkin Lymphoma [96]? Might an 
inflammatory environment, particularly that induced by a high EBV load in IM, allow rogue T 
cell priming, leading in one case to cross-reactive auto-immune recognition of neuronal cells  
and in the other to wrongly polarized T cells that nurture rather than deter lymphoma growth? At 
the same time, the immune response can be used for good rather than ill; adoptive T cell therapy 
has shown how a restoration of virus-specific T cells can successfully treat EBV-driven B-
lymphoproliferative disease [56; Bollard et al, 2012], so how best to exploit these same cellular 
responses to target other EBV-positive malignancies [97]?  Arguably most important of all, how 
best to design a prophylactic vaccine that, even if it cannot prevent primary infection, may limit 
virus load and protect against EBV-associated disease [98]?  As we approach the 50
th
 
anniversary of the discovery of EBV [99], the virus’ challenge to the immunologist remains as 
potent as ever.             
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Figure legends  
Figure 1.  
A schematic view of EBV infection and persistence in the immunocompetent host.  Orally 
transmitted virus establishes a lytic (Lyt) infection of permissive cells in the oropharynx , leading 
to high levels of virus shedding in saliva/throat washings. It is thought that both squamous 
epithelial cells and locally-infiltrating B cells may support this lytic infection; whether de novo-
infected B cells can enter lytic cycle immediately or only after a phase of growth transformation 
is not known. Thereafter the virus colonises the general B cell system via growth-transforming 
latent infections of B cells in local lymphoid tissues such as the tonsil; denoted L3, these cells 
exhibit “latency 3” infection like that seen in LCL cells in vitro. Some L3 cells then down-
regulate the expression of growth-transforming proteins, thereby escaping immune recognition 
and establishing a true antigen-negative form of latency (L0, “latency 0”); such cells are found 
exclusively in the memory B cell pool and re-circulate predominantly between the blood and 
oropharyngeal lymphoid tissues. On occasions, perhaps induced by cognate antigen-driven 
differentiation to plasma cells or by local mucosal signals, latently-infected cells within the B 
cell reservoir reactivate into lytic cycle. The virions thus produced can then seed low-level foci 
of replication/shedding in oropharyngeal epithelial cells, or initiate a new cycle of infection and 
transformation in adjacent B cells, some of which may survive to enter the memory B cell pool 
as above. In the immunocompetent host, many of these events are subject to immune controls. 
Primary EBV infection, as seen in IM patients, induces NK cell activation, large expansions of 
virus-specific CD8
+
 T cells (with lytic antigen reactivities dominant over latent) and smaller 
expansions of virus- specific CD4
+
 T cells (with latent antigen reactivities at least the equal of 
lytic) in the blood. These initial expansions are later culled, leaving lower numbers of virus-
specific memory T cells in the blood of long-term virus carriers. Note, however, that the blood 
picture is not always representative of the situation in lymphoid tissues. Thus, the percentage of 
EBV-specific T cells in IM blood over-estimates that seen in tonsils during acute infection, 
whereas the situation is reversed in long-term carriers where EBV-specific memory populations, 
particularly latent antigen-specific CD8
+
 T cells, are enriched in tonsils. Red arrows denote 
transfer of infectious virions; black arrows denote movement/transition of infected cells; blue 
arrows denote targeting of infected cells by cell-mediated immune responses. 
 
 
Figure 2 
Dynamics of virus load and immune response to primary symptomatic EBV infection.  IM 
patients develop symptoms approximately 4-6 weeks after virus acquisition and this prodromal 
period is indicated as a shaded area on the graphs; dotted lines within this area indicate 
uncertainty about when parameters rise during this period. Virus genome loads : By the time IM 
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symptoms appear, high loads of infectious virus are being shed from sites of virus replication in 
the oropharynx, and high numbers of latently-infected B cells are detectable in the blood. While 
latently-infected B cell numbers fall rapidly over the course of disease, virus shedding in the 
throat typically remains high for several months before decreasing to lower levels. Cell-mediated 
responses : NK cell numbers are transiently raised in IM blood and the cells display an activated 
phenotype. At the same time, large numbers of activated lytic antigen-specific CD8
+
 T cells 
dominate the blood picture, with the response to an individual immunodominant epitope often 
accounting for 5-25% or more of the expanded CD8
+
 T cell population. These numbers fall 
rapidly as the disease resolves.  Latent antigen-specific CD8 responses are less numerous and 
less heavily culled. Primary CD4
+
 T cell responses are also detectable in IM blood but, by 
comparison, are much smaller and even more rapidly culled; individual epitope responses rarely 
exceed 1% of the CD4
+
 T cell pool, with individual latent antigen reactivities dominant over 
lytic. Note that, unlike responses to all other target antigens studied, the CD4
+
 T cell response to 
EBNA1 does not appear until weeks/months after IM.        Antibody responses : By the time IM 
symptoms appear, IgG antibody titres to lytic cycle antigens such as the virus capsid antigen 
(VCA) complex have already peaked and later fall to stable levels.  Likewise IgG antibodies to 
the EBNA2 latent cycle antigen are present but later fall, sometimes below the level of detection, 
whereas IgG responses to EBNA1 first appear months later but then persist for life. Thus an anti-
VCA
+
, anti-EBNA2
+
, anti-EBNA1
- 
serologic picture is diagnostic of primary/recent EBV 
infection, and full resolution of a primary infection is associated with the anti-EBNA1 antibody 
titre exceeding that of anti-EBNA2.  
 
Figure 3 
Antigen-presenting cells and EBV-specific T cell responses: Upper diagrams T cell responses 
may be driven by direct contact with virus-infected B cells themselves, or by viral antigens 
released from infected cells and cross-presented by dendritic cells. Note that all latent and lytic 
cycle proteins tested to date are detectably released from infected cells, with the single exception 
(not shown) of EBNA1. Lower diagrams Using CD8
+
 T cells as an example, effective T cell 
recognition of B cells requires both TCR ligation of the cognate HLA I-peptide complex and 
licensing by SAP-dependent CD244/CD48 and NTBA/NTBA interactions; this licensing fails in 
XLP patients. Dendritic cells do not express CD48 or NTBA and so their recognition by T cells 
is independent of these additional licensing interactions.  
[A] In the immunocompetent host: Two features of EBV-induced CD4
+
 T cell responses, the 
broad spectrum of antigens targeted (including many late lytic cycle proteins) and the delayed 
primary response to EBNA1 (a poorly-released antigen), both suggest a dominant role for 
antigen release and cross-presentation as the main driver of these responses; it seems likely that 
dendritic cells play a key role in such cross-presentation, although EBV-infected B cells can also 
acquire viral antigens released from infected neighbours and cross-present to CD4
+
 T cells. 
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Conversely two features of the EBV-induced CD8
+
 T cell response, the marked focus on 
epitopes from immediate early and some early proteins of the lytic cycle (reflecting epitope 
display on naturally-infected cells) and the rapid primary response to EBNA1 (a poorly-released 
antigen), both suggest that the CD8 response is predominantly driven by direct contact with 
infected B cells. 
[B] In XLP patients : In the absence of SAP, T cell/B cell recognition is impaired. This should 
not affect the antigenic profile of CD4
+
 T cell responses since the main cell-cell interaction 
driving these responses, CD4
+
 T cells and cross-presenting dendritic cells, should be intact. 
However, CD8
+
 T cell responses may now also become dependent upon the cross-presenting 
pathway; as a result, the antigen profile of the CD8 response is predicted to be broader and no 
longer reflect the hierarchy of epitope display on naturally infected B cells. Note that the failure 
of T cell/B cell recognition in XLP also impairs receipt of the TCR-restimulation signals that 
normally regulate CD8
+
 T cell expansions, thereby promoting hyper-expansion of the response 
and its attendant immune pathology. 
 
Figure 4. 
The humanised mouse model of EBV infection : NK cells restrict lytic EBV replication to 
prevent IM symptoms. [A] NOD/scid/c-/- mice are reconstituted  with human immune system 
components using human CD34
+
 haemopoietic stem cells and then experimentally infected with 
EBV [B] Depletion of CD94
+
NKG2A
+
KIR
-
 NK cells does not affect levels of growth-
transformed latently-infected cells (L3) but abrogates control of lytic EBV replication, leading to 
higher numbers of lytically-infected cells (Lyt) in lymphoid tissues. This in turns drives 
increased large CD8
+
 T cell expansions, associated with IM-like symptoms.  In contrast, animals 
retaining NK cells are able to control lytic EBV infection and thereby avoid this lytic antigen-
specific CD8
+
 T cell expansion. 
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